RBC Capital Initiates Coverage On Bicycle Therapeutics with Outperform Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has initiated coverage on Bicycle Therapeutics with an Outperform rating and set a price target of $35.
September 06, 2024 | 9:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has initiated coverage on Bicycle Therapeutics with an Outperform rating and a price target of $35, indicating positive expectations for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $35 by RBC Capital suggests a positive outlook for Bicycle Therapeutics. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100